Search

Your search keyword '"Tibben, M"' showing total 3 results
Start Over Author "Tibben, M" Journal journal of pharmaceutical and biomedical analysis
3 results on '"Tibben, M"'

2. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

Author

van Andel, L, Rosing, H, Lubomirov, R, Avilés, P, Fudio, S, Tibben, M M, Nan-Offeringa, L, Schellens, J H M, Beijnen, J H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
0301 basic medicine, Lurbinectedin, HPLC–MS/MS, Bioanalysis, Lung Neoplasms, Time Factors, Clinical Biochemistry, Liquid-Liquid Extraction, Pharmaceutical Science, Antineoplastic Agents, Urine, Mass spectrometry, 01 natural sciences, Heterocyclic Compounds, 4 or More Rings, Sensitivity and Specificity, Analytical Chemistry, Matrix (chemical analysis), 03 medical and health sciences, Plasma, Liquid chromatography–mass spectrometry, Limit of Detection, Tandem Mass Spectrometry, Drug Discovery, Humans, Spectroscopy, Chromatography, High Pressure Liquid, PM01183, Chromatography, Elution, Chemistry, 010401 analytical chemistry, Extraction (chemistry), Reproducibility of Results, Small Cell Lung Carcinoma, 0104 chemical sciences, 030104 developmental biology, Clinical Trials, Phase III as Topic, RNA Polymerase II, Carbolines
Abstract

Lurbinectedin is a novel highly selective inhibitor of RNA polymerase II triggering caspase-dependent apoptosis of cancerous cells. This article describes the development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay to quantify lurbinectedin in human plasma and urine. Plasma samples were pre-treated with 1 M aqueous ammonia after which they were brought onto supported liquid extraction (SLE) columns. Lurbinectedin was eluted from the columns using tert-butyl methyl ether (TBME). Urine was first diluted in plasma and lurbinectedin was extracted from this matrix by liquid-liquid extraction using TBME. Samples were measured by LC-MS/MS in the positive electron ion spray mode. The method was linear over 0.1-100 ng/mL and 1-1000 ng/mL in plasma and urine, respectively, with accuracies and precisions within ±15% (20% for LLOQ) and below 15% (20% for LLOQ), respectively. The method was developed to support a mass balance study in which patients received a dose of 5 mg lurbinectedin.

Published
2018
Full Text
View/download PDF

3. Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

Author

Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, and Beijnen JH

Subjects
Administration, Oral, Animals, Chromatography, High Pressure Liquid methods, Drug Screening Assays, Antitumor, Humans, Male, Mice, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors pharmacokinetics, Pyrazoles administration & dosage, Pyrazoles pharmacokinetics, Quinolines administration & dosage, Quinolines pharmacokinetics, Reproducibility of Results, Sensitivity and Specificity, Transforming Growth Factor beta antagonists & inhibitors, Protein Kinase Inhibitors blood, Pyrazoles blood, Quinolines blood, Tandem Mass Spectrometry methods
Abstract

Galunisertib is an anti-cancer drug currently evaluated in phase I and II clinical trials. This study describes the development and validation of a bioanalytical assay to quantify galunisertib in human plasma using HPLC-MS/MS. Stable isotope labelled galunisertib was added as internal standard and the analyte and internal standard were extracted from the matrix by protein precipitation using acetonitrile-methanol (50:50, v/v). Final extracts were injected onto a C18 column, gradient elution was applied for chromatographic separation and detection was performed using a triple quadrupole mass spectrometer operating in the positive ion mode. The assay was linear over the range 0.05-10 ng/mL, with acceptable accuracy (bias ranging from -6.1 to 3.1%) and precision (below 5.7% C.V.) values. The applicability of the assay was demonstrated in a pharmacokinetic experiment in mice., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results